证券代码：300871 证券简称：回盛生物 转债代码：123132 转债简称：回盛转债 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2023-003 特定对象调研 分析师会议 媒体采访 业绩说明会 投资者关系 新闻发布会 路演活动 活动类别 现场参观 其他（2023 年湖北辖区上市公司投资者网上集体接待日） 参与单位名称 通过全景路演网络平台参加 2023 年湖北辖区上市公司投资者网上集体接 待日活动的投资者 时 间 2023 年 5 月 25 日 14:30-16:35 地 点 全景网"投资者关系互动平台"（https://ir.p5w.net）网络文字互动 副总经理、财务总监 杨凯杰 董事会秘书 王庆峰 上市公司 接待人员姓名 公司就投资者在本次说明会中提出的问题进行了回复： 1、贵公司泰乐菌素生产开工率达到多少？ 回复：尊敬的投资者，您好！目前公司泰乐菌素生产线开工率 40% 多，正处于爬坡阶段。谢谢！ 投资者关系活动 2、公司宠物制剂产线终止，后续宠物药品生产是外代工吗？ 主要内容介绍 回复：尊敬的投资者，您好！目前公司子公司湖北回盛"片剂/颗粒 剂（含中药提取）"生产线已通过 GMP ...

证券代码：300871 证券简称：回盛生物 转债代码：123132 转债简称：回盛转债 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2023-002 特定对象调研 分析师会议 投资者关系 媒体采访 业绩说明会 活动类别 新闻发布会 路演活动 现场参观 其他 参与单位名称 线上参与公司 2022 年度网上业绩说明会的全体投资者 时 间 2023 年 5 月 9 日 15:30-17:00 地 点 价值在线（https://www.ir-online.cn）网络互动 董事长、总经理 张卫元 | --- | |--------------------| | 独立董事 | | 副董事长 | | 副总经理、财务总监 | | 董事会秘书 | | 保荐代表人 | 上市公司 接待人员姓名 1、公司投资建设年产 2000 吨泰乐菌素、600 吨泰万菌素原料药项 目，是否存在产能消化问题？ 回复：原料-制剂一体化是公司根据行业发展趋势和自身竞争优势制 定的重要战略之一。泰乐菌素原料药是大环内酯类抗生素系列产品的重 要基础原料药，可最终应用于公司多个核心产品（如泰万菌素制剂、替 投资者关系活动 米考星制剂、泰地罗新制 ...

Business Focus - The company focuses on veterinary medicine, primarily in the pig medication sector, with sales revenue and operating profit mainly derived from this segment [5]. - The veterinary medicine industry is transitioning to a high-quality development stage, with increased focus on innovative and effective antimicrobial drugs [33]. - The scale of livestock farming in China has exceeded 70%, leading to increased concentration in the veterinary medicine industry [34]. - The company has established itself among the top 10 in the domestic pig breeding industry and maintains stable partnerships with numerous large-scale breeding enterprises [37]. - The company has obtained 154 veterinary drug approval numbers, with products widely used across various animal sectors including pigs, poultry, aquaculture, ruminants, and pets [38]. Financial Performance - The company's operating revenue for 2022 was ¥1,022,900,792.34, representing a 2.68% increase compared to ¥996,216,817.61 in 2021 [24]. - The net profit attributable to shareholders for 2022 was ¥52,706,475.48, a decrease of 60.33% from ¥132,865,534.22 in 2021 [24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,089,151.68, down 61.74% from ¥115,223,691.93 in 2021 [24]. - The net cash flow from operating activities decreased by 37.91% to ¥96,680,490.85 in 2022 from ¥155,718,489.99 in 2021 [24]. - The total assets at the end of 2022 were ¥2,989,114,303.25, an increase of 9.03% from ¥2,741,662,030.01 at the end of 2021 [24]. Risks and Challenges - The company faces risks from fluctuations in downstream industry demand, particularly in the pig breeding sector, which can impact overall demand for veterinary products [5]. - The company is exposed to risks from significant fluctuations in raw material prices, which directly affect the cost of veterinary drug formulations [6]. - The company has achieved certain success in controlling African swine fever, but any resurgence could negatively impact the pig breeding industry and, consequently, the demand for veterinary products [9]. Research and Development - The company is actively increasing R&D investment in pet medications and expanding market channels to tap into the pet medicine market [36]. - The company has completed the development of 10 new functional pet health products and submitted 10 national patent applications [74]. - The company has established a new independent R&D institution with a registered capital of CNY 10 million to enhance technological innovation [69]. - The company has established partnerships with academic institutions to enhance its research capabilities and drive technological advancements in its product lines [137]. Marketing and Sales Strategy - The marketing strategy has shifted from a "product-oriented" approach to a "value-oriented" approach, focusing on market pain points and improving breeding efficiency [53]. - The company has implemented a production management model combining sales-based production and safety stock, ensuring adequate supply for high-demand products [45]. - The company has adopted a direct sales and distribution model, signing annual cooperation agreements with both large-scale breeding groups and small-scale farmers [45]. Governance and Compliance - The company’s financial report has been verified for accuracy and completeness by its board and management, ensuring transparency for investors [3]. - The governance structure includes a complete system with a general meeting of shareholders, board of directors, supervisory board, and management team, ensuring clear functional roles [128]. - The company has not reported any significant discrepancies in governance compared to legal and regulatory requirements [121]. - The company has a dedicated investor relations section on its official website to maintain good communication with investors [121]. Employee and Management - The total number of employees at the end of the reporting period is 957, with 336 in the parent company and 621 in major subsidiaries [155]. - The company has a strong emphasis on performance-based remuneration for its senior management [144]. - The company has implemented a stock incentive plan to align the interests of management with those of shareholders, which includes the repurchase and cancellation of shares [133]. Environmental and Social Responsibility - The company has actively responded to national carbon peak and carbon neutrality initiatives by optimizing processes to reduce energy consumption and utilizing rooftop resources for photovoltaic power generation [176]. - The company emphasizes strict compliance with environmental regulations and has implemented measures to reduce resource consumption and environmental impact during production [182]. - The company has not engaged in any significant environmental violations or received administrative penalties during the reporting period [176]. Future Outlook - The company aims to achieve breakthroughs in poultry, ruminants, and aquaculture while consolidating its advantages in pig medications [36]. - The company plans to enhance its R&D capabilities, focusing on traditional Chinese veterinary medicine and biological veterinary medicine, to develop new drugs with its own branding [111]. - The company anticipates a gradual recovery in market conditions, projecting improved financial performance in the upcoming fiscal year [136].

Financial Performance - The company's revenue for Q1 2023 was CNY 230,412,076.04, representing a 12.03% increase compared to CNY 205,665,754.61 in the same period last year[6] - Net profit attributable to shareholders reached CNY 14,855,718.00, a significant increase of 634.03% from CNY 2,023,854.94 in the previous year[6] - The net profit after deducting non-recurring gains and losses was CNY 8,945,243.79, up 697.11% from CNY 1,122,203.66 year-on-year[6] - Basic and diluted earnings per share were both CNY 0.09, an increase of 800% compared to CNY 0.01 in the same period last year[6] - Total operating revenue for Q1 2023 was 16,631,467.48, a significant increase from 2,793,791.45 in Q1 2022, representing a growth of approximately 496%[26] - Net profit for Q1 2023 reached 14,855,718.00, compared to 2,023,854.94 in the same period last year, marking a year-over-year increase of about 634%[26] - Basic and diluted earnings per share for Q1 2023 were both 0.09, up from 0.01 in Q1 2022, indicating a substantial improvement in profitability[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,024,445,118.45, a 1.18% increase from CNY 2,989,114,303.25 at the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 3,024,445,118.45, up from CNY 2,989,114,303.25 at the beginning of the year, reflecting a growth of 1.2%[22] - The total current assets reached CNY 1,368,615,054.54, compared to CNY 1,351,475,288.90 at the start of the year, indicating an increase of 1.9%[20] - The total liabilities as of March 31, 2023, were CNY 1,468,156,374.06, slightly up from CNY 1,447,682,082.36 at the beginning of the year, showing an increase of 1.4%[22] - The total non-current assets were CNY 1,655,830,063.91, up from CNY 1,637,639,014.35, reflecting a growth of 1.1%[20] - Short-term borrowings rose to CNY 257,017,934.21 from CNY 220,084,829.04, an increase of 16.8%[21] - The company's retained earnings increased to CNY 391,076,854.19 from CNY 376,221,136.19, a growth of 3.9%[22] - The total equity attributable to the owners of the parent company was CNY 1,556,288,744.39, compared to CNY 1,541,432,220.89 at the beginning of the year, indicating an increase of 1.0%[22] Cash Flow - The company's cash flow from operating activities was negative at CNY -17,180,234.31, slightly worse than CNY -16,025,127.81 in the same period last year, reflecting a decrease of 7.21%[6] - Cash flow from operating activities showed a net outflow of -17,180,234.31, slightly worse than the -16,025,127.81 recorded in Q1 2022[29] - The net cash flow from investing activities improved by 76.49%, amounting to CNY -88,514,280.15 compared to CNY -376,449,232.15 in the previous year[14] - Cash flow from investing activities resulted in a net outflow of -88,514,280.15, compared to -376,449,232.15 in the previous year, indicating a reduction in cash burn[29] - The net cash flow from financing activities surged by 4,596.57% to CNY 64,595,118.87, primarily due to increased borrowings[14] - Cash flow from financing activities generated a net inflow of 64,595,118.87, a significant increase from 1,375,366.95 in Q1 2022, reflecting improved financing conditions[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,202, with the largest shareholder holding 49.86% of the shares[15] Government Subsidies - The company received government subsidies totaling CNY 3,980,605.72 during the reporting period, contributing to its financial performance[8] Operating Costs and Expenses - Total operating costs for Q1 2023 were 220,505,096.35, up from 201,486,255.25 in Q1 2022, indicating a rise of approximately 9.5%[25] - Research and development expenses for Q1 2023 were 9,286,444.32, slightly down from 9,754,406.16 in Q1 2022, showing a focus on cost management in R&D[25] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 395,545,161.51 from CNY 424,044,443.62, representing a decline of 6.1%[19] - The company reported a total cash and cash equivalents balance of 237,472,437.22 at the end of Q1 2023, down from 575,070,614.85 at the end of Q1 2022[30] - The company received cash inflows from investment activities totaling 352,273,935.15, a significant increase from 30,353,258.20 in the previous year, indicating strong investment recovery[29]

证券代码：300871 证券简称：回盛生物 公告编号：2023-034 武汉回盛生物科技股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 武汉回盛生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司 定于 2023 年 05 月 09 日（星期二）15:30-17:00 在"价值在线"（www.ir- online.cn）举办武汉回盛生物科技股份有限公司 2022 年度业绩说明会，与投 会议召开时间：2023 年 5 月 9 日（星期二）15:30-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集：投资者可于 2023 年 5 月 9 日前访问网址 https://eseb.cn/144ZHWhBtzG 或使用微信扫描下方小程序码进行会 前提问，公司将通过本次业 ...

证券代码：300871 证券简称：回盛生物 1 武汉回盛生物科技股份有限公司投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | --- | --- | |-------------------------|-------|-----------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：300871 证券简称：回盛生物 武汉回盛生物科技股份有限公司投资者关系活动记录表 编号：2021-003 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-------|--------------------------------------------------------------|----------------------|------------------------------------------------------------|----------|---------| | 投资者关系 \n活动类别 | | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n现场参观 \n广发证券 | \n \n \n \n周舒玥 | □分析师会议 \n 业绩说明会 \n□路演活动 \n 其他 \n长江证券 | 电话会议 | 高辰星 | | | | 中信证券 | 彭家乐 | 长江证券 | | 顾熀乾 | | | | 中信证券 | 罗 寅 | 华宝基金 | | 陆 恒 | | | | 中信证券 ...

Company Overview - Wuhan Huisheng Biological Technology Co., Ltd. focuses on the research, production, and sales of veterinary drugs, primarily for pigs, while also expanding into other areas such as poultry, aquaculture, pets, and ruminants [2][3]. - The company ranks among the top ten in the domestic veterinary chemical preparations market according to the China Veterinary Drug Association's report [3]. Competitive Advantages - **Research and Development**: The company has established a strong R&D system, collaborating with Huazhong Agricultural University and has received 11 new veterinary drug certificates by the end of 2021, with more expected in 2022 [3][4]. - **Industry Chain Extension**: New raw material projects are set to be completed this year, enhancing production capacity for key raw materials, which will lower costs and improve competitiveness [3][4]. - **Smart Manufacturing**: The company has automated production lines that have passed the new GMP certification, ensuring high-quality production [3][4]. - **Product Quality and Market Share**: A robust quality control system has led to increased market share among major clients [3][4]. Financial Performance - In 2021, the company invested approximately 46.89 million yuan in R&D, a 65.20% increase from the previous year, with plans for continued investment [4][5]. - The sales revenue from the aquaculture sector grew by 169.62% in 2021, marking it as a new growth point for the company [5]. Regulatory Environment - The new GMP standards require all veterinary drug manufacturers to pass inspections by June 1, 2022, with over 900 companies already compliant [4][5]. - The "antibiotic ban" policy is expected to increase demand for preventive medications and alternatives to antibiotics, providing new opportunities for the company's products [5][6]. Future Outlook - The company plans to launch new veterinary drugs, including "Taidirol Injection," which is a new generation of antibiotics with a long-lasting effect [5][6]. - Upcoming raw material projects, including the production of 1,000 tons of Tylosin and 600 tons of Tiamulin, are expected to commence in mid-2022, enhancing production capacity [6]. Challenges - The decline in gross margin in 2021 was primarily due to rising raw material costs and the impact of the pig farming industry's losses [6]. - Short-term investments in projects may increase depreciation costs but are expected to enhance long-term competitiveness and product quality [6].

转债代码：123132 转债简称：回盛转债 证券代码：300871 证券简称：回盛生物 1 武汉回盛生物科技股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | 分析师会议 ...